| Literature DB >> 31817430 |
Naren Gajenthra Kumar1, Daniel Contaifer2, Parthasarathy Madurantakam3, Salvatore Carbone4,5, Elvin T Price2, Benjamin Van Tassell2, Donald F Brophy2, Dayanjan S Wijesinghe2,6,7.
Abstract
Diet is major modifiable risk factor for cardiovascular disease that can influence the immune status of the individual and contribute to persistent low-grade inflammation. In recent years, there has been an increased appreciation of the role of polyunsaturated fatty acids (PUFA) in improving immune function and reduction of systemic inflammation via the modulation of pattern recognition receptors (PRR) on immune cells. Extensive research on the use of bioactive lipids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and their metabolites have illustrated the importance of these pro-resolving lipid mediators in modulating signaling through PRRs. While their mechanism of action, bioavailability in the blood, and their efficacy for clinical use forms an active area of research, they are found widely administered as marine animal-based supplements like fish oil and krill oil to promote health. The focus of this review will be to discuss the effect of these bioactive fatty acids and their metabolites on immune cells and the resulting inflammatory response, with a brief discussion about modern methods for their analysis using mass spectrometry-based methods.Entities:
Keywords: DHA; EPA; FDA regulations; Immune function; PPAR; essential fatty acids; non-essential fatty acids; toll like receptors
Mesh:
Substances:
Year: 2019 PMID: 31817430 PMCID: PMC6950193 DOI: 10.3390/nu11122974
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Fatty acid configuration and their role in inflammation-related pathways. n- omega- position of unsaturation, fatty acid nomenclature XX:Y; XX—number of carbon, Y—number of unsaturated bonds. AA—arachidonic acid, EPA—eicosapentaenoic acid, DHA—docosahexaenoic acid, COX—cyclooxygenase, LTB—leukotriene, PGE—prostaglandin.
Influence of fatty acids and their metabolites on lymphocyte functions. Source—Endogenous/supplement—the fatty acid was supplemented in an in vivo study or enriched in formulations in vitro. Synthetic—fatty acid was used in in-vitro studies. PLA2—phospholipase A2, PGE2—prostaglandin E2.
| Lipid | Source | Immune Cell | Function | Ref. |
|---|---|---|---|---|
| Fatty acids | ||||
| FA 20:4, FA 20:5, FA 22:6 | Endogenous, supplement | Neutrophil | Adherence to endothelia (CD11a and CD 11b) | [ |
| FA 18:3 n-3 | Supplement | Alveolar macrophages | Increased phagocytosis, Increased TNF-αproduction | [ |
| FA 18:3 n-3 | Oral | T-cell | Suppress T cell proliferation | [ |
| FA 20:4 | PLA2-II mediated release of arachidonic acid (only release no metabolism) | Neutrophil | Increased mac-1 (CD-11b/CD18) expression | [ |
| FA 18:0, 18:2, 18:3, 20:4 | Endogenous | Macrophages and hepatocytes | Ligand binding activators of PPAR-α, PPAR-γ | [ |
| FA 18:2 n-6 | Dietary source | Dendritic cells | Reduced infiltration of LN and activation of T-cell. Reduced IL-12 increased IL -10 | [ |
| FA 20:5 | Synthetic | Mast Cells | Decreased activation | [ |
| FA 22:6 n-3 | Synthetic | Dendritic cells | Increased IL-12 | [ |
| FA Metabolites | ||||
| PGE2 | Endogenous | Lymphocytes | Inhibitor TH1 response (IL-12) | [ |
| Leukotriene B4 | Endogenous, supplement | Neutrophil | Adherence to endothelia (CD11a and CD 11b) | [ |
| Inflammasome | Supplement | NLRP3 inflammasome | Increased IL-1β, IL-18 | [ |
Clinical studies involving polyunsaturated fatty acids.
| Study Design | Lipids | Study Endpoints | Results | Ref. |
|---|---|---|---|---|
| Double blind RCT study | Omega-3 long-chain polyunsaturated fatty acids | Allergic symptoms in children from mothers supplemented with 2.7 g omega-3 LCPUFA daily | Fewer allergies in children whose mothers received high omega-3 LCPUFA supplement. | [ |
| REDUCE-IT study—double blind RCT study | Eicosapentaenoic acid | Cardiovascular death | 2 g of EPA twice daily reduce risk of ischemic events. | [ |
| Double blind RCT study | Eicosapentaenoic acid | Reduction of depressive symptoms | Omega-3 supplementation benefit patients with major depressive episode without comorbid anxiety disorder. | [ |
| PREDIMED study random subsample—parallel-group randomized trial | Mediterranean diet | Cardiovascular events | Incidence of cardiovascular events was lower in patients receiving Mediterranean diet supplemented with extra-virgin oil or nuts. | [ |
| PREDIMED study random subsample—parallel-group randomized trial | Mediterranean diet | Effect of HDL particles on reverse cholesterol transport | The diet increased cholesterol efflux, decreased cholesteryl ester transfer protein activity and increased HDL ability to esterify cholesterol. | [ |
| Double blind RCT study | Fish oil n-3-PUFA | Muscle strength and average isokinetic power | n-3 PUFA therapy slows muscle mass decline and function in older adults | [ |
| Double blind RCT study | Fish oil n-3-PUFA | Response of lysophospholipids to obesity | Obesity impact lysophospholipid metabolism abolishing its sensitivity to n-2 PUFA. | [ |
| Compassionate protocol | Fish oil-based lipid emulsion | Resolution of cholestasis (plasma conjugated bilirubin <2 mg/dL) | All survival demonstrated resolution of cholestasis, compared with only 10% of non-surviving. | [ |
| Double blind RCT study | EPA-DHA intake | Creatinine–cystatin C-based GFR | Long term supplementation with 400 mg/d of EPA-DHA provides slower kidney function decline in CKD patients. | [ |
| Open-label randomized study | EPA-DHA intake | Cumulative rate of all-cause death, non-fatal myocardial infarction, and non-fatal stroke | Treatment significantly lowered risk of death and cardiovascular death. | [ |
Figure 2Influence of fatty acids on immune cells as summarized in Table 1. Abbreviations; LFA-1—leukocyte factor antigen-1, IL—interleukin, Th1—T helper type I, TNF-α—tumor necrosis factor alpha, LN—lymph node, cPLA2—cytosolic phospholipase A2, PPAR—peroxisome proliferator-activated receptor, NLRP3—nucleotide-binding and oligomerization domain-like receptor, leucine-rich repeat and pyrin domain–containing 3, ↑—levels increase, ↓—levels decrease.
Figure 3(a) Isobaric overlap (kindly provided by Dr. Paul Baker) typically seen while analyzing lipids. (b) Separation of lipids based on class in reverse phase chromatography in positive and negative mode. (c) Schematic of fatty acid and eicosanoid metabolism and suggested approaches for quantification of bioactive fatty acids and associated oxylipins (PL-eicosanoids).